Liver Transplant/Hepatology/Hepatitis/Liver Failure Clinical Trials

Liver Disease Management & Transplant Program




Hepatitis C  |  Hepatic Encephalopathy  |  Thrombocytopenic  |  Acute Liver Failure

Hepatitis C

Principal Investigator/Contact Information Protocol Title Patient Population Recruitment Period
Principal Investigator:
Natalie Bzowej, MD

Contact:
Allison Gilchrist
415-600-1768
Email GilchrA@cpmcri.org
A randomized, adaptive-design dose finding study to assess the antiviral efficacy and safety of NIM811 administered in combination with Standard of Care (SOC) in relapsed HCV-1 infected patients
Visit the Safety of NIM811 study on ClinicalTrials.gov.
Subjects chronic hepatitis C virus infection who have relapsed after interferon/ribavirin treatment.Open
Principal Investigator:
Natalie Bzowej, MD

Contact:
Allison Gilchrist
415-600-1768
Email GilchrA@cpmcri.org
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple Dose Trial of the Safety, Efficacy, and Pharmacokinetics of ANA598 Administered with Pegylated Interferon and Ribavirin in Treatment-Naïve Genotype 1 Patients with Chronic Hepatitis C Infection
Visit the Chronic Hepatitis C Infection study on ClinicalTrials.gov.
Subjects who have genotype 1, who have never been treated. (treatment naïve).Open
Principal Investigator:
Natalie Bzowej, MD

Contact:
Anna Von Bakonyi, LVN
415-600-1107
Email VonBaka@cpmcri.org
A Phase 2, Randomized, Double-Blind, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug (RO5024048) in Combination with Pegasys® and Copegus® versus the Currently Approved Combination of Pegasys® and Copegus® in Treatment Naive Patients with Chronic Hepatitis C Genotype 1 or 4 Virus Infection
Visit the Chronic Hepatitis C study on ClinicalTrials.gov.
Genotype 1 or 4 subjects who have never been treated. (treatment naive)Closed to enrollment


Back to top

Hepatic Encephalopathy



Principal Investigator/Contact InformationProtocol TitlePatient PopulationRecruitment Period
Principal Investigator:
Dr. Todd Frederick

Contact:
Allison Gilchrist, RN
415-600-17678
Email gilchra@cpmcri.org
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo Controlled, Dose-Ranging Trial to Evaluate the Efficacy, Safety, and Tolerability of AST-120 (Spherical Carbon Adsorbent) for 8 Weeks in the Treatment of Mild Hepatic Encephalopathy
Visit the Mild Hepatic Encephalopat study on ClinicalTrials.gov.
Subjects who have cirrhosis and could be experiencing some of the impairments of mild hepatic encephalopathyOpen


Back to top

Thrombocytopenic

Principal Investigator/Contact InformationProtocol TitlePatient PopulationRecruitment Period
Principal Investigator:
Maurizio Bonacini, MD

Contact:
Catherine Carr
415-600-1369
Email carrca@cpmcri.org
A Phase 2, Randomized, Multicenter, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Efficacy, Safety, and Population Pharmacokinetics of Once-Daily Oral E5501 Tablets Used Up to 7 Days in Subjects with Chronic Liver Diseases and Thrombocytopenia Prior to Elective Surgical or Diagnostic Procedures
Visit Chronic Liver Diseases study on ClinicalTrials.gov.
Subjects who have thrombocytopenia related to chronic liver disease and are scheduled to undergo an elective surgical or diagnostic procedure.Open


Back to top

Acute Liver Failure

Principal Investigator/Contact InformationProtocol TitlePatient PopulationRecruitment Period
Principal Investigator:
Dr. Todd Frederick

Contact:
Nina Topic, RN
415-600-1721
Email topicn@sutterhealth.org
Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Subjects with Acute On Chronic Hepatitis (AOCH) (Vital Therapies-206).
Visit the Acute On Chronic Hepatitis (AOCH) study on ClinicalTrials.gov.
Subjects with acute decompensation of chronic liver disease (cirrhosis)Open
Principal Investigator:
Timothy Davern, MD

Contact:
Katherine Fajardo
415-600-1518
Email fajardk@cpmcri.org
A Multi-Center Trial to Study Acute Liver Failure: Including Acute Liver Injury (ALI)
Visit the Acute Liver Failure study on ClinicalTrials.gov.
Hospitalized patients who have acute liver failure or acute liver injury. Subjects must be a hospitalized patient.Open
Principal Investigator:
Timothy Davern, MD

Contact:
Katherine Fajardo
415-600-1518
Email fajardk@cpmcri.org
Drug-Induced Liver Injury Network (DILIN) Protocol #1- Idiosyncratic Liver Injury Associated with Drugs (ILIAD).
Visit the ILIAD study on ClinicalTrials.gov.
Subjects 2 years or older diagnosed with ILIAD due to medications are isoniazid, phenytoin, clavulanic acid/amoxicillin, valproic acid, trimethoprim-sulfamethoxazole, minocycline and quinolone antibiotics. Subjects 2 years or older who took the same medications but did not develop ILIAD.Open
Principal Investigator:
Timothy Davern, MD

Contact:
Katherine Fajardo
415-600-1518
Email fajardk@cpmcri.org
Drug-Induced Liver Injury Network (DILIN) Protocol #2- A Multicenter, Longitudinal Study of Drug-and CAM-Induced Liver Injury
Visit the DILIN study on ClinicalTrials.gov.
Subjects 2 years who have taken a drug complementary alternative medicine product and developed a liver reaction within the past 6 months.Open
Principal Investigator:
Dr. Todd Frederick

Contact:
Nina Topic, RN
415-600-1721
Email topicn@sutterhealth.org
Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Subjects with Fulminant Hepatic Failure (FHF) (Vital Therapies 202)
Visit the ELAD study on ClinicalTrials.gov.
Subjects who are experiencing signs and symptoms of fulminant hepatic failure (FHF).Coming Soon


updated: 2/2/10


Back to top